CASTLE BIOSCIENCES, INC. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
CASTLE BIOSCIENCES, INC. (CSTL) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $11.21 million for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-04.
Financial Statements › Shareholders' Equity › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2025-08-04
- CASTLE BIOSCIENCES, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $11.21M, a 14.96% decline year-over-year.
- CASTLE BIOSCIENCES, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-03-31 was $11.18M, a 11.80% decline year-over-year.
- CASTLE BIOSCIENCES, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2024-09-30 was $13.03M, a 0.12% decline year-over-year.
- CASTLE BIOSCIENCES, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2024-06-30 was $13.18M, a 2.57% increase year-over-year.
- CASTLE BIOSCIENCES, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $50.32M, a 1.76% decline from fiscal 2023.
- CASTLE BIOSCIENCES, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $51.22M, a 41.02% increase from fiscal 2022.
- CASTLE BIOSCIENCES, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $36.32M, a 67.07% increase from fiscal 2021.
- CASTLE BIOSCIENCES, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2021 was $21.74M, a 161.64% increase from fiscal 2020.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month as first filed | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month as first filed | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|---|---|
| 2025-06-30 | $11.21M 10-Q · filed 2025-08-04 | $22.39M derived: sum of 2 quarters · filed 2025-08-04 | |||||
| 2025-03-31 | $11.18M 10-Q · filed 2025-08-04 | ||||||
| 2024-12-31 | $50.32M 10-K · filed 2025-02-27 | ||||||
| 2024-09-30 | $13.03M 10-Q · filed 2024-11-04 | $26.21M derived: sum of 2 quarters · filed 2025-08-04 | $38.88M derived: sum of 3 quarters · filed 2025-08-04 | ||||
| 2024-06-30 | $13.18M 10-Q · filed 2025-08-04 | $25.85M derived: sum of 2 quarters · filed 2025-08-04 | |||||
| 2024-03-31 | $12.68M 10-Q · filed 2025-08-04 | ||||||
| 2023-12-31 | $51.22M 10-K · filed 2025-02-27 | ||||||
| 2023-09-30 | $13.04M 10-Q · filed 2024-11-04 | $25.89M derived: sum of 2 quarters · filed 2024-11-04 | $39.42M derived: sum of 3 quarters · filed 2024-11-04 | ||||
| 2023-06-30 | $12.85M 10-Q · filed 2024-11-04 | $26.37M derived: sum of 2 quarters · filed 2024-11-04 | |||||
| 2023-03-31 | $13.53M 10-Q · filed 2024-11-04 | ||||||
| 2022-12-31 | $36.32M 10-K · filed 2025-02-27 | ||||||
| 2022-09-30 | $9.20M 10-Q · filed 2023-11-02 | $17.98M derived: sum of 2 quarters · filed 2023-11-02 | $26.40M derived: sum of 3 quarters · filed 2023-11-02 | ||||
| 2022-06-30 | $8.78M 10-Q · filed 2023-11-02 | $17.20M derived: sum of 2 quarters · filed 2023-11-02 | |||||
| 2022-03-31 | $8.42M 10-Q · filed 2023-11-02 | ||||||
| 2021-12-31 | $21.74M 10-K · filed 2023-02-28 | ||||||
| 2021-09-30 | $5.21M 10-Q · filed 2022-11-02 | $9.98M derived: sum of 2 quarters · filed 2022-11-02 | $14.89M derived: sum of 3 quarters · filed 2022-11-02 | $17.85M derived: sum of 4 quarters · filed 2022-11-02 | |||
| 2021-06-30 | $4.77M 10-Q · filed 2022-11-02 | $9.68M derived: sum of 2 quarters · filed 2022-11-02 | $12.64M derived: sum of 3 quarters · filed 2022-11-02 | $14.76M derived: sum of 4 quarters · filed 2022-11-02 | |||
| 2021-03-31 | $4.91M 10-Q · filed 2022-11-02 | $7.87M derived: sum of 2 quarters · filed 2022-11-02 | $9.99M derived: sum of 3 quarters · filed 2022-11-02 | $11.64M derived: sum of 4 quarters · filed 2022-11-02 | |||
| 2020-12-31 | $2.96M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $5.08M derived: sum of 2 quarters · filed 2022-02-28 | $6.73M derived: sum of 3 quarters · filed 2022-02-28 | $8.31M 10-K · filed 2022-02-28 | |||
| 2020-09-30 | $2.12M 10-Q · filed 2021-11-08 | $3.77M derived: sum of 2 quarters · filed 2021-11-08 | $5.35M 10-Q · filed 2020-11-09 | $6.06M derived: sum of 4 quarters · filed 2021-11-08 | |||
| 2020-06-30 | $1.65M 10-Q · filed 2021-11-08 | $3.23M 10-Q · filed 2020-08-10 | $3.94M derived: sum of 3 quarters · filed 2021-11-08 | $4.17M derived: sum of 4 quarters · filed 2021-11-08 | |||
| 2020-03-31 | $1.58M 10-Q · filed 2021-11-08 | $2.29M derived: sum of 2 quarters · filed 2021-11-08 | $2.52M derived: sum of 3 quarters · filed 2021-11-08 | $2.66M derived: sum of 4 quarters · filed 2021-11-08 | |||
| 2019-12-31 | $713.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $942.00K derived: sum of 2 quarters · filed 2021-03-11 | $1.08M derived: sum of 3 quarters · filed 2021-03-11 | $1.25M 10-K · filed 2021-03-11 | |||
| 2019-09-30 | $229.00K 10-Q · filed 2020-11-09 | $229.48K 10-Q · filed 2019-11-12 | $368.00K derived: sum of 2 quarters · filed 2020-11-09 | $536.00K 10-Q · filed 2020-11-09 | $536.71K 10-Q · filed 2019-11-12 | $609.27K derived: sum of 4 quarters · filed 2020-11-09 | |
| 2019-06-30 | $139.00K 10-Q · filed 2020-08-10 | $138.81K 10-Q · filed 2019-09-03 | $307.00K 10-Q · filed 2020-08-10 | $307.23K 10-Q · filed 2019-09-03 | $380.27K derived: sum of 3 quarters · filed 2020-08-10 | $454.66K derived: sum of 4 quarters · filed 2020-08-10 | |
| 2019-03-31 | $168.00K 10-Q · filed 2020-05-11 | $241.27K derived: sum of 2 quarters · filed 2020-05-11 | $315.66K derived: sum of 3 quarters · filed 2020-05-11 | $400.29K derived: sum of 4 quarters · filed 2020-05-11 | |||
| 2018-12-31 | $73.27K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $147.66K derived: sum of 2 quarters · filed 2020-03-10 | $232.29K derived: sum of 3 quarters · filed 2020-03-10 | $294.00K 10-K · filed 2020-03-10 | |||
| 2018-09-30 | $74.39K 10-Q · filed 2019-11-12 | $159.03K derived: sum of 2 quarters · filed 2019-11-12 | $220.73K 10-Q · filed 2019-11-12 | ||||
| 2018-06-30 | $84.63K 10-Q · filed 2019-09-03 | $146.34K 10-Q · filed 2019-09-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |